Hyperglycemia Treatment Market Size, Share, and COVID-19 Impact Analysis By Treatment (Fluid Replacement, Electrolyte Replacement, Insulin Therapy, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies and Online & Retail Pharmacies), and Regional Forecast, 2024-2032

Hyperglycemia is the early stage of diabetes which poses a major threat to human health if not managed. Also, diabetes patients may develop hyperglycemia if they do not control their blood sugar levels or skip a dose of their medication, among other factors. The increasing prevalence of diabetes, especially in emerging countries like India, China, Brazil, etc., is resulting in the rising incidence of hyperglycemia in these countries.

• According to the data published by the International diabetes federation (IDF) in 2021, it was reported that around 74.0 million adults are living with diabetes in India.

The increasing prevalence of hyperglycemia globally is attributed to the shift towards sedentary lifestyles, especially in countries like the U.S., India, China, etc. The major players in the market are focusing on developing new drugs to offer effective treatment options to meet the growing demand from diabetes patients worldwide. This has led to increasing research & development investments to introduce new treatment methods in this market.

• According to the data published by Mary Ann Liebert, Inc., in 2020, it was reported that the prevalence of hyperglycemia is around 36.0% in people of age 18-54 years in the U.S.

However, the potential for adverse reactions while taking insulin or other drugs to treat hyperglycemia is limiting the market expansion. In addition to others, using insulin may have side effects such as edema, muscle cramps, itchiness at the injection site, and rapid weight gain. Patients who inject more insulin than necessary may also cause low blood sugar, which, if left untreated, might result in a coma. All these factors are further responsible for limiting the market growth.

Impact of COVID-19 on the Hyperglycemia Treatment Market

The COVID-19 pandemic has been challenging for the major players in the market as they encountered challenges supplying medications to various countries as a result of a disrupted supply chain due to the various government guidelines and imposed lockdown.

Apart from this, the pandemic offered various opportunities for pharmaceutical companies to develop new drugs for hyperglycemia and expand their pipeline portfolio. Various pharmaceutical companies collaborated with other players to manufacture and develop new treatment options for hyperglycemia.

• For example, in May 2022, Eli Lilly and Company received U.S. FDA approval for a Mounjaro injection to control high blood sugar levels in type-2 diabetes patients used along with following proper diet and exercise.

Additionally, the pandemic has increased the number of people receiving home care treatment, including insulin therapy, medications, and lifestyle adjustments to manage hyperglycemia effectively.

Key Insights

The report will cover the following key insights:

• Prevalence of Diabetes, By Key Countries, 2022.


• New Product Launches, By Key Players.


• Key Industry Developments- Mergers, Partnerships, & Acquisitions.


• Impact of COVID-19 on the Market.

Analysis by Treatment

Based on treatment, the market is segmented into fluid replacement, electrolyte replacement, insulin therapy, and others. The increasing focus of key players in research & development investments to develop and launch new insulin products used to treat hyperglycemia effectively is responsible for driving the insulin therapy segment growth. This along with the focus of industry players collaborating with other companies to obtain the distribution rights of drugs that are used to control hyperglycemia to market them in developing and under-developing countries.

• In August 2022, Eris Lifesciences, an Indian pharmaceutical company, entered into a licensing agreement with Biocon Biologics, a biotechnology company, to market insulin glargine in India. The launch of insulin glargine is expected to take place in 2023. Insulin glargine is a modified form of human insulin used to manage both type 1 and type 2 diabetes.

Regional Analysis

North America dominates the hyperglycemia treatment market due to the ongoing clinical trials on various drugs, advanced healthcare infrastructure in the U.S. and Canada, and the increasing number of pharmaceutical companies. Additional factors contributing to the market growth include the rising approval of new products by regulatory bodies across North America.

Asia Pacific is anticipated to grow at a faster pace during the forecast period. This is due to the presence of a large patient population suffering from diabetes and the growing adoption of new treatment options in countries like China, India, etc., which is further responsible for the market growth in this region.

• For example, in December 2022, Glenmark Pharmaceuticals launched a triple fixed-dose combination of teneligliptin with pioglitazone and metformin for type-2 diabetes patients in India.

Key Players Covered

The report will include the profiles of key players such as Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Novo Nordisk A/S, Bristol-Myers Squibb Company, Sanofi, AstraZeneca, Teva Pharmaceutical Industries Ltd., and others.

Segmentation

Key Industry Developments

• December 2022: Abbott announced that its FreeStyle Libre 3 sensor can now be used with the mylife Loop solution from partners Ypsomed and CamDiab. This integration creates an automated system for delivering insulin based on real-time glucose data. This Automated Insulin Delivery (AID) solution is available in Germany and will be rolled out to other European countries starting in 2023.


• October 2022: Glenmark Pharmaceuticals Limited launched the Lobeglitazone drug in India for type 2 diabetes patients who are resistant to insulin. This drug improves sugar levels in uncontrolled diabetics and offers treatment for insulin resistance patients in India.


• January 2020: Novo Nordisk A/S received U.S. FDA approval for Fiasp insulin injection. This injection is used for treating children with diabetes and is available for adults in three different dosing options.


• In November 2019, Sanofi announced the positive results in phase 3 clinical trials of Toujeo, an insulin glargine injection for children and adolescents aged 6-17 years with type 1 diabetes.